CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening ...

Novartis International AG / AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families . Processed and transmitted by West Corporation. The issuer is solely ...

AveXis has posted top-line data from a phase 1 trial of its gene therapy against spinal muscular atrophy (SMA). All 15 patients were event-free at 13.6 months of age, a significant improvement ...

BASEL, Switzerland, May 24, 2019 /PRNewswire/ -- AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma ® (onasemnogene abeparvovac-xioi) for ...

After receiving FDA breakthrough therapy status for its lead candidate in July, gene therapy company AveXis has released promising new safety and efficacy data. AVXS-101 is being developed to ...

AveXis’ gene therapy for spinal muscular atrophy, Zolgensma receives European approval: Basel Wednesday, May 20, 2020, 09:00 Hrs [IST] AveXis, a Novartis company, announced the European Commission (EC ...

Novartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene therapy Zolgensma to a seriously ill child in Belgium, saying compassionate use rules do no ...

Gene therapy biotech AveXis raised $65 million in Series D cash to advance a potential one-time treatment for the rare spinal muscular atrophy, a debilitating disease with no approved therapies.

Based on those positive results, AveXis has advanced AVXS-101 into a pivotal trial in SMA type 1, and launched a Phase I trial of the gene therapy candidate in SMA type 2, both in the U.S.

More: New gene therapy treatment could hit $1M per patient because of additional costs AveXis said it has been working on clinical studies for the treatment of spinal muscular atrophy, or SMA. The ...

AveXis, a Novartis company, today announced innovative access programs for Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with spinal ...

BASEL, Switzerland, May 24, 2019 /PRNewswire/ -- AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma(®) (onasemnogene abeparvovac-xioi ...